Modulation of multidrug resistance by cepharanthine in fresh human gastrointestinal tumor cells

被引:0
|
作者
Hotta, T [1 ]
Tanimura, H [1 ]
Yamaue, H [1 ]
Iwahashi, M [1 ]
Tani, M [1 ]
Tsunoda, T [1 ]
Tamai, M [1 ]
Noguchi, K [1 ]
Mizobata, S [1 ]
Arii, K [1 ]
Terasawa, H [1 ]
机构
[1] WAKAYAMA MED COLL,DEPT SURG 2,WAKAYAMA 640,JAPAN
关键词
multidrug resistance; P-glycoprotein; doxorubicin; cepharanthine;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Resistance to doxorubicin (DOX) is mainly due to the effect of P-glycoprotein encoded by the multidrug resistance (MDR) gene. Cepharanthine (CEP) has been shown to circumvent multidrug resistance in P-glycoprotein-expressing cell lines. In the present study, we investigated the augmentation of DOX sensitivity by CEP using an MTT assay, and assessed the correlation between DOX sensitivity and P-glycoprotein expression by flow cytometry, in highly purified fresh human tumor cells obtained from 73 cancer patients. DOX sensitivity was decreased in proportion to P-glycoprotein expression. The cytotoxicity of DOX was increased by CEP in tumor cells possessing low DOX P-glycoprotein sensitivity. Moreover, there was a significant correlation between the effect of Doxorubicin CEP on cytotoxicity and P-glycoprotein expression. Thus, CEP might be able Cepharanthine to circumvent DOX resistance in cancer patients.
引用
收藏
页码:153 / 157
页数:5
相关论文
共 50 条
  • [31] Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides
    Stewart, AJ
    Canitrot, Y
    Baracchini, E
    Dean, NM
    Deeley, RG
    Cole, SPC
    BIOCHEMICAL PHARMACOLOGY, 1996, 51 (04) : 461 - 469
  • [32] Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitro
    Hoffmann, Katrin
    Xiao, Zhi
    Franz, Clemens
    Mohr, Elvira
    Serba, Susanne
    Buechler, Markus W.
    Schemmer, Peter
    CANCER CELL INTERNATIONAL, 2011, 11
  • [33] PSC 833 modulation of multidrug resistance to paclitaxel in cultured human ovarian carcinoma cells leads to apoptosis
    Duraj, J
    Sedlak, J
    Bies, J
    Chovancova, J
    Chorvath, B
    ANTICANCER RESEARCH, 2002, 22 (6A) : 3425 - 3428
  • [34] Transport proteins of the ABC family and multidrug resistance of tumor cells
    Stavrovskaya, A. A.
    Stromskaya, T. P.
    BIOCHEMISTRY-MOSCOW, 2008, 73 (05) : 592 - 604
  • [35] YB-1 Protein and Multidrug Resistance of Tumor Cells
    Stavrovskaya, Alla
    Stromskaya, Tatyana
    Rybalkina, Ekaterina
    Moiseeva, Natalia
    Vaiman, Andrey
    Guryanov, Sergey
    Ovchinnikov, Lev
    Guens, Gelena
    CURRENT SIGNAL TRANSDUCTION THERAPY, 2012, 7 (03) : 237 - 246
  • [36] Transport proteins of the ABC family and multidrug resistance of tumor cells
    A. A. Stavrovskaya
    T. P. Stromskaya
    Biochemistry (Moscow), 2008, 73 : 592 - 604
  • [37] Cepharanthine hydrochloride reverses P-glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway
    Huang, Chen-Zheng
    Wang, Ya-Feng
    Zhang, Yan
    Peng, You-Mei
    Liu, Yi-Xian
    Ma, Fang
    Jiang, Jin-Hua
    Wang, Qing-Duan
    ONCOLOGY REPORTS, 2017, 38 (04) : 2558 - 2564
  • [38] Effect of block architecture on the ability of polyalkylene oxides to overcome multidrug resistance of tumor cells
    Pavlov, D. N.
    Alexandrova, N. A.
    Krylova, O. O.
    Pohl, P.
    Melik-Nubarov, N. S.
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2006, 16 (04) : 259 - 265
  • [39] Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitro
    Katrin Hoffmann
    Zhi Xiao
    Clemens Franz
    Elvira Mohr
    Susanne Serba
    Markus W Büchler
    Peter Schemmer
    Cancer Cell International, 11
  • [40] MULTIDRUG-RESISTANCE GENE (MDR1) EXPRESSION IN HUMAN TUMOR XENOGRAFTS
    ABE, Y
    NAKAMURA, M
    OHNISHI, Y
    INABA, M
    UEYAMA, Y
    TAMAOKA, N
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1994, 5 (06) : 1285 - 1292